Israeli biotech company Matricelf has successfully completed another usability trial with human implants, replacing the injured spinal cord of a living pig, the company announced Tuesday.
Follow Israel Hayom on Facebook, Twitter, and Instagram
Matricelf, founded in 2019, develops autologous (bone marrow) implants for the regeneration of damaged tissues by using patients' own cell components and external cell components.
The live pig trial simulated the anticipated surgical procedure in humans, both in terms of the flow of brain and spinal fluids, and in terms of the bleeding that might be caused near the site of the injury. During the trial, two neurosurgeons positioned implants originating from human tissues in the pig's injured spinal cord.
After the implants were placed, a substitute Dura Patch was grafted into the injured spinal cord and membranes surrounding the spinal cord were sutured back together.
Matricelf VP R&D Dr. Tamar Harel Adar said: "We are delighted to announce that the implants developed by the company, designed for treating traumatic injuries to the spinal cord have been successfully placed in the spinal cord of a living pig."
Matricelf CEO Dr. Asaf Toker added, "This is an important milestone in strengthening the company's technological knowledge and advances us towards the vision we have set for ourselves – to be a world leading Israeli company in the field of tissue engineering."
